SRB 17
Alternative Names: SRB-17Latest Information Update: 29 Jul 2024
At a glance
- Originator SunRock Biopharma
- Developer Debiopharm; SunRock Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Jun 2024 Preclinical trials in Cancer in Switzerland (Parenteral) (SunRock Biopharma pipeline, June 2024)